Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Interferon‐α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its use is limited by inflammation‐mediated toxicity, leading to treatment discontinuation in 10‐30% of patients. Ruxolitinib, a potent anti...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Mikkelsen, Stine Ulrik, Kjær, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Andersen, Christen Bertel Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Fassi, Daniel El, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits‐Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, Skov, Vibe, Hasselbalch, Hans Carl
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089176/
https://ncbi.nlm.nih.gov/pubmed/29932310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1619
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia